VRTXVERTEX PHARMACEUTICALS INC ...

Nasdaq vrtx.com


$ 447.20 $ -10.07 (-2.2 %)    

Tuesday, 28-May-2024 15:59:58 EDT
QQQ $ 454.82 $ 1.73 (0.38 %)
DIA $ 398.57 $ -2.04 (-0.52 %)
SPY $ 530.36 $ 0.37 (0.07 %)
TLT $ 91.26 $ -1.31 (-1.43 %)
GLD $ 225.37 $ 2.27 (1.05 %)
$ 446.88
$ 454.06
$ 0.00 x 0
$ 0.00 x 0
$ 445.40 - $ 454.17
$ 320.01 - $ 457.66
1,375,250
na
116.68B
$ 0.50
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 02-15-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 05-02-2023 03-31-2023 10-Q
6 02-10-2023 12-31-2022 10-K
7 10-28-2022 09-30-2022 10-Q
8 08-05-2022 06-30-2022 10-Q
9 05-06-2022 03-31-2022 10-Q
10 02-09-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 07-30-2021 06-30-2021 10-Q
13 04-30-2021 03-31-2021 10-Q
14 02-11-2021 12-31-2020 10-K
15 10-30-2020 09-30-2020 10-Q
16 07-31-2020 06-30-2020 10-Q
17 05-01-2020 03-31-2020 10-Q
18 02-13-2020 12-31-2019 10-K
19 10-31-2019 09-30-2019 10-Q
20 08-01-2019 06-30-2019 10-Q
21 05-01-2019 03-31-2019 10-Q
22 02-13-2019 12-31-2018 10-K
23 10-25-2018 09-30-2018 10-Q
24 07-26-2018 06-30-2018 10-Q
25 04-27-2018 03-31-2018 10-Q
26 02-15-2018 12-31-2017 10-K
27 10-30-2017 09-30-2017 10-Q
28 07-28-2017 06-30-2017 10-Q
29 04-28-2017 03-31-2017 10-Q
30 02-23-2017 12-31-2016 10-K
31 10-31-2016 09-30-2016 10-Q
32 08-01-2016 06-30-2016 10-Q
33 05-03-2016 03-31-2016 10-Q
34 02-16-2016 12-31-2015 10-K
35 10-30-2015 09-30-2015 10-Q
36 08-04-2015 06-30-2015 10-Q
37 05-04-2015 03-31-2015 10-Q
38 02-13-2015 12-31-2014 10-K
39 11-06-2014 09-30-2014 10-Q
40 07-31-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 arcturus-therapeutics-early-cystic-fibrosis-trial-results-encouraging---analyst-cautiously-optimistic

Arcturus Therapeutics' early Phase 1 results show ARCT-032 is safe and well-tolerated, with promising improvements in lung ...

 walmart-vertex-pharmaceuticals-and-more-on-cnbcs-final-trades

Walmart Inc. reported a "really strong" quarter, with e-commerce sales surging 21%. Adjusted EPS was 60 cents.

 pfizer-freeport-mcmoran-vertex-pharmaceuticals-and-a-major-tech-stock-on-cnbcs-final-trades

Pfizer is looking to build on the success of its COVID-19 vaccine rollout by introducing a direct-to-consumer medicines platform.

 us-stocks-eye-fourth-positive-session-despite-hawkish-fed-remarks-disney-palantir-tumble-treasury-yields-fall-whats-driving-markets-tuesday

Wall Street experienced a quiet session during morning trading on Tuesday, influenced by a lack of significant economic data an...

 rbc-capital-maintains-sector-perform-on-vertex-pharmaceuticals-raises-price-target-to-424

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Sector Perform and raises the price...

 hc-wainwright--co-reiterates-buy-on-vertex-pharmaceuticals-maintains-462-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and maintains $462 pr...

 needham-reiterates-hold-on-vertex-pharmaceuticals

Needham analyst Joseph Stringer reiterates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Hold.

 piper-sandler-maintains-overweight-on-vertex-pharmaceuticals-raises-price-target-to-456

Piper Sandler analyst Christopher Raymond maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the pr...

 vertex-reiterates-fy24-financial-guidance-including-product-revenue-guidance-of-1055b-1075b-est-10702b

Vertex's product revenue guidance includes expectations for continued growth in CF as well as for the launch of CASGEVY in ...

 vertex-pharmaceuticals-q1-2024-adj-eps-476-beats-406-estimate-sales-2690b-beat-2579b-estimate

Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings of $4.76 per share which beat the analyst consensus estimate o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION